Publications by authors named "K van Straalen"

34 Publications

Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration.

Br J Dermatol 2021 Sep 9. Epub 2021 Sep 9.

Department of Epidemiology, Mailman School of Public Health, Columbia University, NY, NY, USA.

Hidradenitis suppurativa (HS) is a prevalent and debilitating skin disease that arises from pathological inflammation in the hair follicle, particularly those located within the axillae, groin, and buttocks. Disease management is difficult and there are many unmet medical needs. There is a high degree of clinical heterogeneity. HS can be limited to the presentation of prototypical skin lesions for some patients, while for others it presents as a disease with multi-organ or systemic involvement.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.20749DOI Listing
September 2021

Prevalence of Central Sensitization in Patients With Hidradenitis Suppurativa.

JAMA Dermatol 2021 Aug 18. Epub 2021 Aug 18.

Department of Dermatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.

Importance: Chronic pain is one of the most prominent symptoms of hidradenitis suppurativa (HS) and an independent domain in the core outcome set for HS. Previously, the chronic, recurrent, inflammatory nature of HS was hypothesized to induce central sensitization (CS; alteration and amplification of pain perception). However, evidence for this hypothesis is currently lacking.

Objective: To determine the prevalence of CS in patients with HS compared with sex- and age-matched controls.

Design, Setting, And Participants: This was a cross-sectional, survey-based, case-control study conducted from February to November 2020 that included all consecutive adult patients with HS attending the outpatient clinic of the Department of Dermatology of the Erasmus University Medical Center Rotterdam, in Rotterdam, the Netherlands. Age- and sex-matched controls without chronic inflammatory dermatologic diseases were recruited from the same department.

Main Outcomes And Measures: The main outcome was the Central Sensitization Inventory (CSI) score (ranging from 0-100) as a screening tool for presence of CS. Based on current literature, a score of 40 or higher was deemed to indicate the presence of CS.

Results: Overall, 100 patients with HS (median [SD] age, 34.5 [27.3-47.0] years; 71 [71%] female) and 100 controls (median [SD] age, 33.5 [27.0-48.8] years; 71 [71%] female) were included, of which 36% and 12%, respectively, had a CSI score of 40 or higher (P < .001). Multivariate logistic regression showed that patients with HS had 4.46 (95% CI, 1.89-10.52; P = .001) times the odds of having a positive CSI compared with controls. In addition, CS was significantly associated with previously diagnosed depression (odds ratio, 6.16; 95% CI, 2.81-13.54; P < .001). No association between CSI score and disease severity was found.

Conclusions And Relevance: In this cross-sectional, case-control study, patients with HS had more than 4 times the odds of having CS, indicated by a positive CSI, compared with age- and sex-matched controls. This new insight in the presence of CS in patients with HS raises the question of whether we are adequately measuring and treating HS-associated pain. Active screening for CS and depressive symptoms in patients with a discrepant pain experience is recommended.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2021.2918DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374732PMC
August 2021

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.

Drugs 2021 Aug 20;81(12):1397-1410. Epub 2021 Jul 20.

Department of Dermatology, Erasmus University Medical Center, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.

Hidradenitis suppurativa (HS) is a chronic, recurrent, auto-inflammatory skin disease originating from the hair follicles. The typical inflammatory nodules, abscesses, and draining sinus tracts (tunnels) are characterized by a massive influx of neutrophils, macrophages, B-cells, plasma cells, T helper (Th)1, Th17 cells and upregulation of pro-inflammatory cytokines such as IL-1, IL-17, IL-12/23, and TNF-α. Over the last decades, several clinical trials evaluated the clinical efficacy of different biologics targeting these pro-inflammatory cytokines, in particular TNF-α and IL-1. However, adalimumab is still the only registered drug for HS. This review discusses biologics and small molecules with high level of evidence for their clinical application, provides guidance on when and how to use these biologics and small molecules in clinical practice, and elaborates on the combination with medical and surgical treatment options beyond the current guidelines. Furthermore this review provides an overview of potential biologics and small molecules currently under investigation for novel targets in HS such as IL-36, C5a, Janus kinase family members, CD-40, LTA4 and CXCR1/2.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-021-01566-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352818PMC
August 2021

No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa.

J Invest Dermatol 2021 Jul 9. Epub 2021 Jul 9.

Department of Pathology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2021.03.037DOI Listing
July 2021

Hidradenitis suppurativa - Body-Mass-Index zu Beginn der Erkrankung.

J Dtsch Dermatol Ges 2021 Mar;19(3):437-439

Department of Dermatology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.14433_gDOI Listing
March 2021
-->